Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse.

Authors:
Alexandre Briguet Isabelle Courdier-Fruh Mark Foster Thomas Meier Josef P Magyar

Neuromuscul Disord 2004 Oct;14(10):675-82

MyoContract Ltd, Hammerstrasse 25, CH-4410 Liestal, Switzerland.

Duchenne muscular dystrophy is a severe X-linked hereditary disease caused by the absence of functional dystrophin. The dystrophin-deficient mdx-mouse strain is a widely used animal model for dystrophin-deficiency. Several therapeutic approaches for muscular dystrophy have been proposed by different laboratories. In order to compare the efficacy of these therapies in the mdx-mouse, it is essential to implement standardized protocols for the assessment of functional and histological parameters in this mouse model. Here, we determine that the minimal 'Feret's diameter' is a geometrical parameter that allows for reliable measure of muscle fiber cross-sectional size. Using this geometrical parameter we calculate variance coefficients of the muscle fiber size and provide reference values for the quantitative assessment of dystrophic symptoms in frequently investigated muscles of wild-type and mdx-mouse. In addition, we compare the variance coefficients of the muscle fiber size with the percentage of muscle fibers with centralized nuclei; another histological hallmark of muscular dystrophy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nmd.2004.06.008DOI Listing
October 2004

Publication Analysis

Top Keywords

muscular dystrophy
16
muscle fiber
12
fiber size
8
variance coefficients
8
geometrical parameter
8
coefficients muscle
8
histological parameters
8
quantitative assessment
8
parameter allows
4
minimal 'feret's
4
diameter' geometrical
4
allows reliable
4
'feret's diameter'
4
reliable measure
4
fiber cross-sectional
4
hallmark muscular
4
measure muscle
4
muscle
4
determine minimal
4
model determine
4

Altmetric Statistics


Show full details
1 Total Shares
1 Citations

Similar Publications

Effects of Mouthpiece Noninvasive Ventilation on Speech in Men With Muscular Dystrophy: A Pilot Study.

Authors:
Deanna Britton Elizabeth Pullen Jeannette D Hoit Joshua O Benditt

Am J Speech Lang Pathol 2021 Mar 2:1-9. Epub 2021 Mar 2.

Division of Pulmonary and Critical Care Medicine, University of Washington Medical Center, Seattle.

Purpose The use of noninvasive ventilation (NIV) is on the rise as an alternative to tracheostomy for individuals with neuromuscular disorders with life-prolonging and quality-of-life benefits. This pilot study was designed to determine if mouthpiece NIV (M-NIV) alters speech in individuals with muscular dystrophy (MD). Method Eight men (23-44 years), seven with Duchenne MD and one with Becker MD, who used daytime M-NIV, were asked to sustain phonation, count, and read under three conditions: (a) (no instructions), (b) (cued to use M-NIV with all speaking breaths), and (c) (as tolerated). Read More

View Article and Full-Text PDF
March 2021
Similar Publications

The role of imaging in characterizing the cardiac natural history of Duchenne muscular dystrophy.

Authors:
Simon Lee Marc Lee Kan N Hor

Pediatr Pulmonol 2021 Mar 2. Epub 2021 Mar 2.

Department of Pediatrics, The Heart Center, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio, USA.

Duchene muscular dystrophy (DMD) is a rare but devastating disease resulting in progressive loss of ambulation, respiratory failure, DMD-associated cardiomyopathy (DMD-CM), and premature death. The use of corticosteroids and supportive respiratory care has improved outcomes, such that DMD-CM is now the leading cause of death. Historically, most programs have focused on skeletal myopathy with less attention to the cardiac phenotype. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Management of rhythm disorders in Duchenne muscular dystrophy: Is sudden death a cardiac or pulmonary problem?

Authors:
Jeffrey Bennett Naomi J Kertesz

Pediatr Pulmonol 2021 Mar 2. Epub 2021 Mar 2.

The Heart Center, Nationwide Children's Hospital, Columbus, Ohio, USA.

Dystrophin deficiency results in the cardiomyopathy of variable onset and deficiency. Myocardial scarring commonly results in cardiac dysfunction, with both atrial and ventricular dysrhythmias. Heart failure, rather than arrhythmia burden, remains the strongest cardiac predictor of mortality in this patient population. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model.

Authors:
Zachary M Howard Lisa E Dorn Jeovanna Lowe Megan D Gertzen Pierce C Ciccone Neha Rastogi Guy L Odom Federica Accornero Jeffrey S Chamberlain Jill A Rafael-Fortney

JCI Insight 2021 Mar 2. Epub 2021 Mar 2.

Department of Physiology & Cell Biology, The Ohio State University College of Medicine, Columbus, United States of America.

Gene replacement for Duchenne muscular dystrophy (DMD) with micro-dystrophins has entered clinical trials, but efficacy on preventing heart failure is unknown. Although most DMD patients die from heart failure, cardiomyopathy is undetectable until the teens so efficacy from trials in young boys will be unknown for a decade. Available DMD animal models were sufficient to demonstrate micro-dystrophin efficacy on earlier onset skeletal muscle pathology underlying loss of ambulation and respiratory insufficiency in patients. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Cardiac medication management in Duchenne muscular dystrophy.

Authors:
Samuel G Wittekind Chet R Villa

Pediatr Pulmonol 2021 Mar 1. Epub 2021 Mar 1.

The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

There have been significant improvements in the skeletal muscle and respiratory care for patients with Duchenne muscular dystrophy (DMD) over the last two decades. This has resulted in longer expected survival as many patients will live into their 20s and 30s. This timeline has resulted in a greater proportion of patients experiencing heart failure and cardiac-related mortality. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap